Checking in With Oxford Nanopore Stock

Regular readers know that we don’t get distracted or unnerved by dropping stock prices. It’s natural to feel a bit panicky. You know how many of our article titles on gene-sequencing stocks last year were variations on: “XXX Stock Plummets: Why We’re Not Jumping to Our Death?” About 15% of our Nanalyze Disruptive Tech Portfolio is weighted in life sciences – and nearly all of that is linked to gene-sequencing stocks. If you’re in it for the long haul, you don’t bail unless you’ve lost faith in your investment thesis. We still believe genomics and gene-sequencing technologies will be key drivers in areas like precision medicine and longevity, especially in monitoring and treating diseases such as cancer.

The market leader in next-generation sequencing, Illumina (ILMN), has looked like anything but that with its failed GRAIL acquisition last year. A couple of competitors playing the long game with long-read sequencing (LRS) appear to be gaining traction. While we like Pacific Biosciences (PACB) – another failed Illumina acquisition – we ended up committing to Oxford Nanopore Technologies (ONT.L). 

Become a premium member and get access to hundreds of premium articles, reports and additional content.

Nanalyze Premium is your comprehensive guide to investing in disruptive technologies. Read by the top investment banks, management consultancies, VCs, and research houses. Trusted by over 100,000 institutional and retail investors. Covering disruptive technologies for over 18 years.